- Home
- BCAB vs ASBP Comparison
BCAB vs ASBP Comparison
Compare BCAB & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | ASBP |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 7.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCAB | ASBP |
|---|---|---|
| Price | $4.47 | $1.08 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 810.3K | 526.8K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.05 |
| 52 Week High | $6.52 | $2.45 |
Technical Indicators
Market Signals| Indicator | BCAB | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 78.12 | 52.08 |
| Support Level | $0.36 | $0.32 |
| Resistance Level | $6.52 | $1.29 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | 0.45 | 0.03 |
| Stochastic Oscillator | 66.88 | 69.23 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.